FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfilePTC Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
PTCT
PTC Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for PTC Therapeutics, Inc. (PTCT) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPTCT
PTCT
PTC Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
PTCT
  1. Home
  2. Stocks
  3. PTC Therapeutics, Inc.

PTC Therapeutics, Inc.

🇺🇸PTCT•NASDAQ

PTC Therapeutics, Inc.

🇺🇸PTCT•NASDAQ
Market cap
$4.71B

Your view on PTCT

Mkt Cap
$4.71B
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About PTC Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Matthew B. Klein F.A.C.S.,
Headquarters
100 Corporate Court, Warren, NJ, US
Industry
Biotechnology
Sector
Healthcare
CEO
Matthew B. Klein F.A.C.S.,
Headquarters
100 Corporate Court, Warren, NJ, US
Description

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders.

Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases.

The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil.

The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F.

Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for PTC Therapeutics, Inc.. Starting points for PTC Therapeutics, Inc.: EPS -$1.27, beta 0.51 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for PTC Therapeutics, Inc.. Trailing twelve-month EPS for PTC Therapeutics, Inc. stands at -$1.27. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
Analysts' target$102.89average of 9 firms, last 12 months
Current price—

Buy

Targets, low to high

$102.89

Low $75.00

Middle $104.00

High $137.00

Analyst ratings

9 firms, last 12 months
  • Strong Buy0
  • Buy8
  • Hold1
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$0.35$0.47$0.53$2.73
Lowest estimate−$3.73$0.28−$0.39$1.49
Highest estimate$5.20$0.66$0.99$4.47
Number of analysts3477
A year ago−$1.671−$0.031$7.781—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$330.38M$316.83M$1.32B$1.43B
Lowest estimate$309.50M$295.00M$1.30B$1.33B
Highest estimate$349.54M$338.66M$1.34B$1.56B
Number of analysts831010
A year ago$164.68M$272.55M$1.73B—
Growth vs a year ago+100.6%+16.2%−23.7%—
Recent rating and target changes (15)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for PTC Therapeutics, Inc.. PTC Therapeutics, Inc. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold PTCT20 companies · 8 funds
Compare PTCT with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
BBIOBridgeBio Pharma, Inc.HealthcareBiotechnology$14.8B
BMRNBioMarin Pharmaceutical Inc.HealthcareBiotechnology$11.7B
CAPRCapricor Therapeutics, Inc.HealthcareBiotechnology$439.6M
DYNDyne Therapeutics, Inc.HealthcareBiotechnology$2.9B
IONSIonis Pharmaceuticals, Inc.HealthcareBiotechnology$4.4B
KRYSKrystal Biotech, Inc.HealthcareBiotechnology$9.2B
RAREUltragenyx Pharmaceutical Inc.HealthcareBiotechnology$1.7B
SLDBSolid Biosciences Inc.HealthcareBiotechnology$697.6M
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
FTREFortrea Holdings Inc.HealthcareNASDAQ$1.8B
FULCFulcrum Therapeutics, Inc.HealthcareNASDAQ$281.8M
GALTGalectin Therapeutics Inc.HealthcareNASDAQ$177.2M
GANXGain Therapeutics, Inc.HealthcareNASDAQ$42.6M
GBIMGlobeImmune, Inc.HealthcareOTC$575
GBLXGB Sciences, Inc.HealthcareOTC$122,121
GDTCCytoMed Therapeutics LimitedHealthcareNASDAQ$8.9M
GENBGenerate Biomedicines, Inc.HealthcareNASDAQ$1.2B
GENSFGenus plcHealthcareOTC$2.5B
GERNGeron CorporationHealthcareNASDAQ$560.9M
GHRSGH Research PLCHealthcareNASDAQ$1.2B
GLABFGemina Laboratories Ltd.HealthcareOTC$3.8M
ETFs holding PTC Therapeutics, Inc.
TickerFundFund assets% of the fund
IJRiShares Core SP Small-Cap ETF$103.8B in assets0.29%
XBIState Street SPDR S&P Biotech ETF$10.0B in assets1.36%
IWMiShares Russell 2000 ETF$76.6B in assets0.17%
VTIVanguard Total Stock Market ETF$689.2B in assets0.01%
PSCHInvesco S&P SmallCap Health Care ETF$188M in assets2.78%
PBEInvesco Biotechnology & Genome ETF$438M in assets2.27%
JSMDJanus Henderson Small/Mid Cap Growth Alpha ETF$1.0B in assets1.00%
JSMLJanus Henderson Small Cap Growth Alpha ETF$379M in assets0.93%

Largest holders first, then the funds most concentrated in PTCT.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold PTC Therapeutics, Inc., and how their positions are changing. At a $4.71B market value, institutional positions materially move PTC Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by PTC Therapeutics, Inc. executives and directors. Shares of PTC Therapeutics, Inc. have traded between $35.95 and $77.45 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for PTC Therapeutics, Inc.. Coverage tracks PTC Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of PTC Therapeutics, Inc.

PTCT AnalysisWeak
Past
1
Growth
5
Health
1
Profit
1
Value
1